Literature DB >> 24583626

Outcomes following second allogeneic haematopoietic transplants using fludarabine-melphalan conditioning.

I Bilmon1, I Nivison-Smith2, M Hertzberg3, D Ritchie4, M Greenwood5, A Spencer6, G Kennedy7, A Bryant8, J Moore9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24583626     DOI： 10.1038/bmt.2014.23

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  10 in total

1.  Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

Authors:  B E Shaw; G J Mufti; S Mackinnon; J D Cavenagh; R M Pearce; K E Towlson; J F Apperley; R Chakraverty; C F Craddock; M A Kazmi; T J Littlewood; D W Milligan; A Pagliuca; K J Thomson; D I Marks; N H Russell
Journal:  Bone Marrow Transplant       Date:  2008-08-25       Impact factor: 5.483

2.  Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?

Authors:  Sergio Giralt
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

3.  Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.

Authors:  A Bryant; I Nivison-Smith; E S Pillai; G Kennedy; A Kalff; D Ritchie; B George; M Hertzberg; S Patil; A Spencer; K Fay; P Cannell; L Berkahn; R Doocey; R Spearing; J Moore
Journal:  Bone Marrow Transplant       Date:  2013-09-23       Impact factor: 5.483

4.  Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.

Authors:  A Bosi; D Laszlo; M Labopin; J Reffeirs; M Michallet; E Gluckman; P E Alessandrino; F Locatelli; J P Vernant; J Sierra; J P Jouet; F Frassoni
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants.

Authors:  Brian T Hill; Brian J Bolwell; Lisa Rybicki; Robert Dean; Matt Kalaycio; Brad Pohlman; Shawnda Tench; Ronald Sobecks; Steven Andresen; Edward Copelan
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-14       Impact factor: 5.742

Review 6.  ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse?

Authors:  Monica S Thakar; Stephen J Forman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 7.  Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.

Authors:  Giuseppe Luigi Banna; Savina Aversa; Vanna Chiarion Sileni; Adolfo Favaretto; Cristina Ghiotto; Silvio Monfardini
Journal:  Crit Rev Oncol Hematol       Date:  2004-09       Impact factor: 6.312

8.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.

Authors:  M Eapen; S A Giralt; M M Horowitz; J P Klein; J E Wagner; M-J Zhang; M S Tallman; D I Marks; B M Camitta; R E Champlin; O Ringdén; C N Bredeson; R Martino; R P Gale; M S Cairo; M R Litzow; M deLima
Journal:  Bone Marrow Transplant       Date:  2004-10       Impact factor: 5.483

9.  A retrospective review of the outcome after second or subsequent allogeneic transplantation.

Authors:  Meirav Kedmi; Igor B Resnick; Liliane Dray; Memet Aker; Simcha Samuel; Benjamin Gesundheit; Shimon Slavin; Reuven Or; Michael Y Shapira
Journal:  Biol Blood Marrow Transplant       Date:  2009-04       Impact factor: 5.742

10.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change.

Authors:  Maximilian Christopeit; Oliver Kuss; Jürgen Finke; Ulrike Bacher; Dietrich Wilhelm Beelen; Martin Bornhäuser; Rainer Schwerdtfeger; Wolfgang Andreas Bethge; Nadezda Basara; Martin Gramatzki; Johanna Tischer; Hans-Jochem Kolb; Lutz Uharek; Ralf G Meyer; Donald Bunjes; Christof Scheid; Hans Martin; Dietger Niederwieser; Nicolaus Kröger; Hartmut Bertz; Hubert Schrezenmeier; Christoph Schmid
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.